TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26920816

Group type: EXPERIMENTAL
Intervention: Bipolar temporary ventricular epicardial pacing leads
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unipolar temporary ventricular epicardial pacing leads
Number of subjects: 50
Study: 25033291

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg) + Praziquantel (40 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (3× (100 mg artesunate + 250 mg mefloquine)) + Praziquantel (40 mg/kg)
Number of subjects: 61
Study: 23032322

Group type: EXPERIMENTAL
Intervention: SOC+HEX (Hextend 6% hetastarch in lactated electrolyte buffer)
Number of subjects: 281

Group type: COMPARATOR
Intervention: SOC (crystalloid plus blood products)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: HEX (in ER and OR)
Number of subjects: 281
Study: 20308616

Group type: EXPERIMENTAL
Intervention: Standard care plus bromocriptine for 8 weeks (PPCM-Br)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (PPCM-Std)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard care plus bromocriptine (PPCM-Br)
Number of subjects: 20
Study: 18490845

Group type: EXPERIMENTAL
Intervention: Kampo (two capsules containing powdered ginseng 250 mg, powdered oriental bezoar 50 mg, and powdered glycyrrhiza 50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (corn starch)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Kampo
Number of subjects: 10
Study: 15727498

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg/70 kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.75 mg/70 kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline iv
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Drug reinforcement opportunity (fentanyl 1.5 mg/70 kg iv)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Money reinforcement opportunity
Number of subjects: 8
Study: 12601441

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10599652

Group type: EXPERIMENTAL
Intervention: 8 fractions of 2 Gy external beam irradiation (n = 101)
Number of subjects: 205

Group type: COMPARATOR
Intervention: 8 fractions of 0 Gy (sham treatment, n = 104)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 8 fractions of 2 Gy external beam irradiation
Number of subjects: 205

Group type: COMPARATOR
Intervention: 8 fractions of 0 Gy (sham treatment)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Visual acuity in the presence of classic CNV (treatment group)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Visual acuity in the presence of classic CNV (control group)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Visual acuity in patients with occult CNV (treatment group)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Visual acuity in patients with occult CNV (control group)
Number of subjects: 205
Study: 7854516

Group type: EXPERIMENTAL
Intervention: High-level vagus nerve stimulation (presumed therapeutic dose)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Low-level vagus nerve stimulation (presumed subtherapeutic dose)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High-level vagus nerve stimulation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Low-level vagus nerve stimulation
Number of subjects: 114
Study: 2048560

Group type: COMPARATOR
Intervention: rhGM-CSF
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 81
Study: 7015799

Group type: EXPERIMENTAL
Intervention: Sustained release quinidine 0.4 g twice a day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Verapamil 80 mg three times a day
Number of subjects: 53
Study: 31073884

Group type: EXPERIMENTAL
Intervention: Oily fish (300 g/week)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Poultry (control)
Number of subjects: 199
Study: 29338563

Group type: EXPERIMENTAL
Intervention: New Perspectives (NP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 101
Study: 27128545

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24452701

Group type: EXPERIMENTAL
Intervention: Personal digital assistant training and support for eight weeks by an occupational therapist
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard rehabilitation including use of non‐electronic memory aids
Number of subjects: 42
Study: 22192386

Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad flap (PBFPF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Classic buccal sliding flap
Number of subjects: 22
Study: 20147875

Group type: EXPERIMENTAL
Intervention: Education program
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Education + Physiotherapy program
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 348
Study: 17935517

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(-1) ointment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tacrolimus 0.3 mg g(-1) ointment
Number of subjects: 50
Study: 16295337

Group type: EXPERIMENTAL
Intervention: Computerised learning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Integrative learning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combination of integrative and computerised learning
Number of subjects: 50
Study: 11927525

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR) < 2.5 after angioplasty
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: CFVR before PTCA
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: CFVR in reference artery
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Low CFVR at the end of the procedure
Number of subjects: 379

Group type: COMPARATOR
Intervention: Patients with CFVR < 2.5 at the end of the procedure
Number of subjects: 379
Study: 9563887

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 450 mg/m2 i.v. for 5 days followed by 15 mg/kg i.v. weekly (arm 1)
Number of subjects: 199

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus levamisole 50 mg p.o. every 8 h for 3 days every 2 weeks (arm 2)
Number of subjects: 199
Study: 7665996

Group type: EXPERIMENTAL
Intervention: Hi-Poly diet (n = 22)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Hi-Mono diet (n = 20)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Human Milk diet (n = 25)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups (Hi-Mono, Hi-Poly, Human Milk)
Number of subjects: 67
Study: 2510604

Group type: EXPERIMENTAL
Intervention: MMC + UFT (A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: MMC + tegafur (B)
Number of subjects: 29
Study: 31005927

Group type: EXPERIMENTAL
Intervention: One-time colonoscopy (n=4000)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Annual faecal immunochemical test (FIT) (n=8000)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Annual risk-adapted screening strategy (n=8000)
Number of subjects: 20000
Study: 28002447

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 60
Study: 25112970

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 9
Study: 21659897

Group type: EXPERIMENTAL
Intervention: High habitual physical activity (>500-1200 MET · min · wk(‐1))
Number of subjects: 58610

Group type: COMPARATOR
Intervention: Low habitual physical activity (≤ 100 MET · min · wk(‐1))
Number of subjects: 58610

Group type: EXPERIMENTAL
Intervention: Higher physical activity
Number of subjects: 58610

Group type: EXPERIMENTAL
Intervention: High habitual physical activity
Number of subjects: 58610
Study: 20044242

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 100 microg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 300 microg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 900 microg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18781665

Group type: EXPERIMENTAL
Intervention: Maintenance interpersonal psychotherapy (IPT-M)
Number of subjects: 131
Study: 16374685

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation at a dosage of 3.1 ± 0.6 mg/kg/day for 9 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional antifailure drugs
Number of subjects: 15
Study: 12357147

Group type: EXPERIMENTAL
Intervention: 8-mg OROS formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8-mg IR formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OROS formulation
Number of subjects: 12
Study: 9187165

Group type: EXPERIMENTAL
Intervention: Oral theophylline at the established optimal dose (range, 300 to 700 mg) plus inhaled placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral placebo plus inhaled (40 microg) ipratropium
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of theophylline and ipratropium
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral and inhaled placebo
Number of subjects: 19
Study: 2007362

Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg daily (N = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (N = 24)
Number of subjects: 49
Study: 7124726

Group type: EXPERIMENTAL
Intervention: 7.05% NaCl (osmotic activity equivalent to 15 ml of 23.5% NaCl)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50% dextrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 20
Study: 31473000

Group type: EXPERIMENTAL
Intervention: Vaccine based on the attenuated AlHV‐1 C500 strain, administered as prime and boost inoculations one month apart.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Culture medium mixed with Emulsigen® (control group).
Number of subjects: 146
Study: 27898183

Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg twice daily (EXE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 30
Study: 25327775

Group type: EXPERIMENTAL
Intervention: Office evaluation plus urodynamic studies (UDS)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Office evaluation (OE)
Number of subjects: 630
Study: 25099425

Group type: EXPERIMENTAL
Intervention: Media literacy curriculum
Number of subjects: 1170
Study: 22227168

Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual community care (control)
Number of subjects: 200
Study: 19508989

Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Expectantly managed fetuses with CDH of variable severity
Number of subjects: 40
Study: 17921706

Group type: EXPERIMENTAL
Intervention: Breast conserving surgery (BCS) plus radiation therapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast conserving surgery (BCS) alone
Number of subjects: 0
Study: 15067339

Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU) for 1 year in patients receiving surgery and radiotherapy (SR)
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 1542

Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU) for 1 year in patients with pelvic lymph node metastases
Number of subjects: 1542
Study: 11340355

Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day) in normotensive patients (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo in normotensive patients (group B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day) in hypertensive patients (group C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo in hypertensive patients (group D)
Number of subjects: 22
Study: 9526893

Group type: EXPERIMENTAL
Intervention: a.m. training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: p.m. training
Number of subjects: 12
Study: 7758055

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours
Number of subjects: 88

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg, given as intermittent intravenous infusions every 6 hours
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 88

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 88
Study: 2100659

Group type: EXPERIMENTAL
Intervention: Anode Iontophoresis using Strontium Chloride Solution (9%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anode Iontophoresis using Strontium Chloride gel (9%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cathode Iontophoresis using Sodium Fluoride solution (2%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cathode Iontophoresis using Sodium Fluoride gel (2%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 60
Study: 373108

Group type: EXPERIMENTAL
Intervention: Neophyllin (4 or 8 tablets, each containing 56 mg proxyphylline and 84 mg diprophylline)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neophyllin (8 tablets) with prior inhalation of 0.5 mg salbutamol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neo-Biphyllin (4 slow release coated tablets, 75 mg teophylline each)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Proxyphylline (in Neophyllin)
Number of subjects: 16
Study: 31713940

Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors (at least 3 years use)
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Finasteride (at least 3 years use)
Number of subjects: 2003
Study: 31302234

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 32
Study: 28156049

Group type: EXPERIMENTAL
Intervention: STEPS-TECH intervention group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 26025794

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib for 3 days followed by oral celecoxib for 4 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: COX-2-specific inhibitors
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufficient postoperative analgesia
Number of subjects: 90
Study: 23978944

Group type: EXPERIMENTAL
Intervention: G-CSF priming
Number of subjects: 183

Group type: COMPARATOR
Intervention: G-CSF post-chemotherapy
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Late consolidation with autologous stem cell transplantation
Number of subjects: 183

Group type: COMPARATOR
Intervention: One consolidation cycle
Number of subjects: 183
Study: 22491395

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT)
Number of subjects: 80
Study: 19538744

Group type: EXPERIMENTAL
Intervention: Design effect formula for multicenter studies
Number of subjects: 0
Study: 17207028

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/day for 3 days)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Cefcapene pivoxil hydrochloride (300 mg/day for 3 days)
Number of subjects: 930

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 930
Study: 15311830

Group type: EXPERIMENTAL
Intervention: STN-DBS ON
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: STN-DBS OFF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age-matched normal subjects)
Number of subjects: 10
Study: 11806608

Group type: EXPERIMENTAL
Intervention: Less palatable beverage exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral or palatable beverage exposure
Number of subjects: 0
Study: 9730318

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 10074756

Group type: EXPERIMENTAL
Intervention: X-ray tube angulation of 5 degrees or less
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: X-ray tube angulation of more than 5 degrees
Number of subjects: 8
Study: 2636644

Group type: EXPERIMENTAL
Intervention: Low protein diet (0.4 g/kg body wt/day of protein and 0.1 g/kg body wt/day of essential amino acids)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Unrestricted protein intake (Control)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD + EAA)
Number of subjects: 57
Study: 342628

Group type: EXPERIMENTAL
Intervention: Monovalent A/New Jersey/76 influenza virus vaccines (two-dose regimens)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Split-virus and whole-virus vaccines
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Two whole-virus vaccines
Number of subjects: 264
Study: 30590811

Group type: EXPERIMENTAL
Intervention: Mild OSA (AHI 5 to 14.9 events/hour)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Moderate OSA (AHI 15 to 29.9 events/hour)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate OSA (overall)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate OSA in young and middle-aged adults
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate OSA in adults older than 60 years
Number of subjects: 744
Study: 27844212

Group type: EXPERIMENTAL
Intervention: Hydrogel (Treatment, n=35)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (n=31)
Number of subjects: 78
Study: 25413898

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 24064159

Group type: EXPERIMENTAL
Intervention: Jaw support device used during dental scaling sessions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no device used) during dental scaling sessions
Number of subjects: 31
Study: 21522097

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no oral clonidine)
Number of subjects: 60
Study: 20137491

Group type: EXPERIMENTAL
Intervention: Emergency endoscopic variceal ligation plus octride (EVL group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Octride alone (octride treatment group)
Number of subjects: 101
Study: 16885180

Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin (10 mg/kg/day) for 14 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thrice-daily tobramycin (divided into three equal doses every 8 hours)
Number of subjects: 33
Study: 14713803

Group type: EXPERIMENTAL
Intervention: 4 mg tolterodine ER once daily for 12 weeks
Number of subjects: 986

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 986
Study: 11216078

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 0
Study: 9041666

Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-cell DTP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular vaccines with individually purified components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-cell and component acellular vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Component acellular vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular vaccine recipients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 0
Study: 8193869

Group type: EXPERIMENTAL
Intervention: Endoscopic management of GER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoluminal methods
Number of subjects: 0
Study: 3253217

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg administered at 21h00
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered at 09h00
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered at 21h00
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg administered at 09h00
Number of subjects: 12
Study: 31690004

Group type: EXPERIMENTAL
Intervention: BBPAS (Brain Breaks Physical Activity Solutions)
Number of subjects: 322
Study: 26840038

Group type: EXPERIMENTAL
Intervention: Low fasting blood glucose (<70 mg/dL)
Number of subjects: 18610

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (100-125 mg/dL)
Number of subjects: 18610

Group type: EXPERIMENTAL
Intervention: Diabetes (≥126 mg/dL, use of antidiabetic medication and/or self-report)
Number of subjects: 18610
Study: 25548316

Group type: EXPERIMENTAL
Intervention: Early support
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Late support
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control
Number of subjects: 297
Study: 24257266

Group type: EXPERIMENTAL
Intervention: POWERS (physical activity only)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: POWERS(plus) (physical activity plus nutrition)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 21715542

Group type: EXPERIMENTAL
Intervention: T(4)+I
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: T(4)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: I
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1024
Study: 19151017

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16304699

Group type: EXPERIMENTAL
Intervention: True exposure to RF field (1 W/kg SAR) for 30 min via a 900 MHz GSM mobile phone.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham exposure (control condition).
Number of subjects: 40
Study: 15172710

Group type: EXPERIMENTAL
Intervention: Tenecteplase 50 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10780756

Group type: EXPERIMENTAL
Intervention: HFA-MDI (fenoterol hydrobromide 50 microg and ipratropium bromide 20 microg)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: CFC-MDI (Berodual/Bronchodual)
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: HFA-MDI
Number of subjects: 2027

Group type: COMPARATOR
Intervention: CFC-MDI
Number of subjects: 2027